Insilico Medicine
Public companyHK1 field
Where it works
| Technology | ||
|---|---|---|
| Longevity biotechGenerative AI drug discovery company that tests candidates such as rentosertib against aging clocks. | Generative AI drug discovery company that tests candidates such as rentosertib against aging clocks. | insilico.com |
Events
| Date | Event | ||
|---|---|---|---|
| Sep 7, 2026 | Rentosertib trial data read out on six proteomic aging clocksdoi.org· Breakthrough· Longevity biotech | Longevity biotech | Breakthrough |
| Jun 3, 2025 | Nature Medicine publishes Phase 2a trial of AI-discovered drug rentosertibdoi.org· Breakthrough· Longevity biotech | Longevity biotech | Breakthrough |
| Nov 12, 2024 | Insilico reports positive Phase 2a results for its AI-designed IPF druginsilico.com· Milestone· Longevity biotech | Longevity biotech | Milestone |
Funding
| Date | Round | Amount | |
|---|---|---|---|
| Dec 31, 2025 | IPO | $293M | pharmaphorum.com |
About
- Source
- insilico.com (official, added by seed)
- First seen
- Sep 25, 2026
- Last seen
- Sep 25, 2026
| Date | Change | ||
|---|---|---|---|
| Sep 25, 2026 | Insilico MedicineCompany in Longevity biotech: Joined a field, Generative AI drug discovery company that tests candidates such as rentosertib against aging clocks. | seed | insilico.com |
| Sep 25, 2026 | Insilico MedicineCompany: Added | seed | insilico.com |